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Objectives: Dapagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor 
approved for the treatment of adults with type 2 diabetes (T2DM). This study com-
pared the cost-effectiveness of dapagliflozin versus a sulfonylurea (SU) added to 
metformin in persons with T2DM inadequately controlled on metformin alone in 
Colombia. MethOds: A discrete event simulation model (Cardiff diabetes model) 
based on UKPDS 68 was used to simulate disease progression and to estimate the 
economic and health treatment consequences in people with T2DM. Epidemiologic 
and clinical efficacy parameters were obtained from the literature. The cost of medi-
cation was obtained from country level price data, SISMED and Farmaprecios; the 
cost of macro- and microvascular events was based on POS tariffs, SOAT Manual 
and consultation with a local expert. Costs were expressed in US dollars [Exchange 
rate: 1,790.6 Colombian pesos = 1$]. A 20-year time horizon was assumed. Costs and 
health outcomes were discounted at 3% annually. Deterministic and probabilistic 
sensitivity analyses (PAS) were performed. Results: The total direct cost of the 
dapagliflozin + MET group over 20 years was higher than that of the SU added to 
metformin group ($11,482,424 vs. $8,942,315). Treatment with dapagliflozin resulted 
in a greater number of quality-adjusted life years (QALYs) compared to SU com-
bination (10,861 vs. 10,439).The calculated Incremental Cost-Effectiveness Ratio 
(ICER) for dapagliflozin compared to SU was $ 6,023 per QALY gained. Using WHO’s 
criteria, dapagliflozin compared to SU treatment strategy has a 85% probability of 
being highly cost-effective (ICER< 1 GDP per capita) and 100% probability of being 
cost-effective (ICER ≤ 3 GDP per capita).The results were robust to sensitivity analy-
sis. cOnclusiOns: This study demonstrated that dapagliflozin in combination 
with metformin would be a cost-effective treatment option for patients who are 
inadequately controlled with metformin monotherapy in Colombia.
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Objectives: To evaluate the long-term cost effectiveness of once daily biphasic 
insulin aspart 30 (BIAsp 30) versus insulin glargine (IGlarg) treating people with 
type 2 diabetes mellitus (T2DM) based on social perspective in China. MethOds: 
The validated and peer-reviewed CORE Diabetes Model was employed to simulate 
disease progression and determine the total direct medical cost, life years (LYs) and 
quality-adjusted life years (QALYs) over 30 years. Simulated cohorts and treatment 
effects were based on the Chinese subgroup (n= 422) in the EasyMix study (identifier 
in ClinicalTrials.gov: NCT01123980) which was an open-label, randomized, two-arm 
and multicentre trial among insulin-naïve people with T2DM. Treatment costs were 
based on insulin doses in the trial and market retail prices in China. Management 
and complication costs were obtained from Chinese published data in 2011 and 
adjusted to the price level of 2012 with consumer price index. An annual discount-
ing rate of 3% was used for both costs and health outcomes. One-way sensitivity 
analyses were performed. Results: Treatment with BIAsp 30 was associated with 
LY gain of 0.09 (13.66 vs. 13.57) and QALY gain of 0.08 (9.72 vs. 9.64) compared with 
IGlarg over 30 years. In terms of total average cost per patient, BIAsp 30 was less 
costly than IGlarg (CNY -46,441, CNY 265,166 vs. 311,607) which was mainly induced 
by lower treatment and management cost (CNY-43,037, CNY 160,863 vs. 203,900) 
and complication cost (CNY -3404, CNY 104,303 vs. 107,707). Sensitivity analyses 
demonstrated robustness of the results. cOnclusiOns: For people with T2DM 
insufficiently controlled on OADs in China, treatment with once daily BIAsp 30 
was projected to be associated with improved life expectancy and reduced direct 
medical cost compared to IGlarg. BIAsp 30 represented a dominant treatment option 
compared to IGlarg for people with T2DM failing to achieve adequate control with 
OADs in China.
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Objectives: Long-term safety trials for new antidiabetic therapies are beginning 
to provide an alternative data source to inform the burden of patients with high 
cardiovascular (CV) risk who are of concern to payers, but are often excluded from 
efficacy trials. An economic model was used to anticipate the availability of CV 
safety outcome data from ongoing trials and assess the clinical, economic and 
quality of life impacts in patients with different high risk profiles. MethOds: A 
discrete event simulation model was developed to capture 6 types of macrovas-
cular events and 2 key treatment events among patients with diabetes at high 
CV risk due to coronary heart disease (CHD), stroke and/or peripheral artery dis-
ease (PAD). Risk of clinical events depended on demographics and event history 
per UKPDS equations. Costs and utility values were based on published literature. 
Model outputs included event rates, CV-related costs and quality-adjusted life-years 
(QALYs). Results: Over a lifetime, in an example population with mean age of 
60 years, mean HbA1C of 8.5%, 70% CHD history, 30% stroke history and 30% PAD 
history, the CV event rate was 25.1/100-patient-years and annual per-patient cost 
was $12,776. This translated into 10.5 QALYs overall, ranging from 9.3 (patients with 
stroke history) to 11.2 (patients with CHD only) QALYs. A new intervention that 
reduces all CV event risks by 20%, results in 12.2 QALYs and annual cost of $10,611 
for the overall population. These burdens vary by up to 14% for plausible values of 
event risk after multiple events, with the burden among patients with stroke his-
tory being most sensitive. cOnclusiOns: The clinical burden of CV events and the 
associated cost of care for patients with diabetes vary with baseline patient history 
and are subject to significant uncertainty. CV safety trials may provide clinical data 
to better quantify those burdens.
and needle. Results: 1) 614 patients with T2DM were surveyed and 71.45% used 
SMBG. For SMBG users, annual costs of glucometers were CNY 212.99; annual costs 
of test strips were CNY 825.55, estimated by multiplying average price (CNY 4.41) and 
frequency (3.60 per week); in total, SMBG cost CNY 1038.54 per person per year; 2) 
For insulin users, annual cost of insulin pens were CNY 396.34, estimated by average 
price (CNY 281.09) and frequency (1.41 per year); annual costs of needles were CNY 
634.20, estimated by average price (CNY 3.1) and frequency (204.58 per year, average 
reuse= 17.05 times); in total, self-injection cost CNY 1030.54 per person per year; 3) 
49.35% of surveyed patients used both insulin and SMBG. For this subgroup, annual 
costs of glucometers were CNY 199.05; annual costs of test strips were CNY 941.99, 
estimated by average price (CNY 4.41) and frequency (4.08 per week); In total was 
CNY 1141.04 per person per year. cOnclusiOns: SMBG and self-injection caused 
considerable economic burdens to patients with T2DM in major cities in China, and 
more attention should be given to their out-of-pocket payment incurred by self-used 
devices and supplies.
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Objectives: To investigate the frequency and cost of insulin pen needles reuse, 
and explore the factors that associated with needles reuse for insulin-treated dia-
betes patients in China. MethOds: A questionnaire-based survey was conducted 
in 7 medical centres across China from June to September of 2012. Type 1 and type 
2 diabetes patients treated with insulin were included in the study. The data were 
analysed by descriptive analysis, Spearman correlation analysis, K-W and M-W 
U test using SPSS 19.0. Results: 592 eligible respondents (30 type 1 and 562 type 
2 diabetes patients) were included. One single needle was used 10.57 times base 
on 5% trimmed mean (8 times in median). 89.2% of patients reuse needles and 
60.5% reuse > 6 times. Among type 1 and type 2 diabetes, needles use frequencies 
base on 5% trimmed mean were 7.19 times (6 times in median) and 10.76 times 
(9 times in median), reuse of needles were 86.7% and 89.4%, needles reuse> 6 
times were 36.7% and 61.7%, respectively. Annual cost of needles was 237.0 CNY, 
estimated by the needle price of 2013 (NovoFine 32GTip, Novo Nordisk). The cost 
would be 2504.9 CNY/year if needles were used 1 time only. Economics burden was 
the most important factor of needles reuse for 68.9% of patients. Needles reuse 
was statistically and positively associated with age, diabetes duration, number of 
complications, value of fasting blood glucose, insulin injections times and dose, 
and was negative associated with income, with P-value< 0.05. cOnclusiOns: 
Needles reuse for insulin injection was a common phenomenon in insulin-treated 
diabetes patients in China. Economic burden was the main reason of needles 
reuse. Other influencing factors of needles reuse included age, diabetes-related 
health status and insulin use.
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Objectives: To describe the prevalence, frequency and cost of SMBG, and explore the 
factors that influence SMBG for insulin-treated diabetes patients in China. MethOds: 
A questionnaire-based survey was conducted in 7 medical centres across China from 
June to September of 2012. Type 1 and type 2 diabetes patients treated with insulin 
were included in the study. The data were analysed by descriptive analysis, Spearman 
correlation analysis, K-W and M-W U test using SPSS 19.0. Results: 602 eligible 
respondents (4.98% type 1 and 95.02% type 2 diabetes patients) were included. 85.0% 
of patients practiced SMBG with the frequency of 0.61±0.94 times/day. Among type 1 
and type 2 diabetes patients, the prevalence and frequency of SMBG were 90.0% and 
1.05 times/day, 84.8% and 0.59 times/day, respectively. Taking global recommended 
SMBG frequency into account, only 18.76% of type 2 diabetes patients conducted 
SMBG ≥ 1 time/day, and 7.4% of type 1 diabetes patients conducted SMBG ≥ 3 times/
day. Annual cost of SMBG was 1170 CNY, estimated by the market price of 5 CNY/
test trip. 20.5% of patients thought the cost of test trips was the most important 
factor to SMBG use. SMBG frequency was statistically and positively correlated with 
frequency and doses of insulin daily use, frequency and related cost of hypoglycae-
mia, drug cost, frequency and cost of hospitalization and clinical visit, with P-value 
< 0.05. cOnclusiOns: SMBG was not conducted enough in insulin-treated diabetes 
patients in China. Economic burden of test trips was one of the main barriers to 
SMBG use. Factors influencing SMBG included insulin use, hypoglycaemia, drug costs, 
frequency and cost of hospitalization and clinic visit.
PDB56
DaPagliflozin versus sulfonylurea as an aDD-on theraPy to 
MetforMin: a Cost-effeCtiveness analysis in ColoMBia
Elgart J.F.1, Prestes M.2, Gonzalez L.3, Aschner P.4, Garrido Lecca S.5, Aiello E.6, Jimenez C.7, 
Gagliardino J.J.3
1CENEXA – Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro 
Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2CENEXA. Centro de Endocrinología 
Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, Argentina, Buenos Aires, Argentina, 
3CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro 
Colaborador OPS/OMS), Buenos Aires, Argentina, 4Pontificia Universidad Javeriana, Bogota, 
Colombia, 5Bristol-Myers Squibb Company, Lima, Peru, 6Bristol-Myers Squibb Company, Buenos 
Aires, Argentina, 7Bristol-Myers Squibb Company, Bogota, Colombia
A248  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
were driven by drug and treatment costs associated with myocardial infarction. The 
total cost of saxagliptin/metformin XR group over 20 years was lower than SU plus 
MET treated group (US$ 14,454,257 vs. US$ 14,735,176). Treatment with saxagliptin/
metformin XR resulted in a greater number of quality-adjusted life years (QALYs) 
and life-years gained (LYG) than the SU combination (10,203 vs. 9,955 and 12,207 vs. 
12,190 respectively). Cost-effectiveness results were robust according to sensitiv-
ity analysis. cOnclusiOns: according to the model cost-effectiveness results in 
Colombia, saxagliptin/metformin XR FDC would be the dominant treatment option 
compared to SU as add-on to MET, for people with T2DM after failure of treatment 
only with MET.
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Objectives: CANA and DAPA are sodium glucose co-transporter 2 inhibitors indi-
cated for the treatment of adults with T2DM as monotherapy and as add-on combi-
nation therapy with other antihyperglycemic agents. The objective of this analysis 
was to evaluate the cost-effectiveness of using CANA 300mg versus using DAPA 
10mg in dual therapy (with MET background) in patients with inadequate A1C 
control. MethOds: A validated health economics model, Economic and Health 
Outcomes (ECHO)–T2DM, was used to estimate 30-year outcomes associated with 
using each treatment in patients as an add-on to MET monotherapy. Treatment 
effects for A1C, weight and the probability of hypoglycemia were obtained from 
a Bayesian Network Meta-Analysis (NMA) of 52 (+/-4) week trials of subjects 
inadequately controlled on MET monotherapy. For parameters unavailable in the 
NMA (i.e., SBP, LDL, HDL and rates of AEs), values were obtained from a post-hoc 
analysis of pooled data from two trials of subjects receiving CANA and MET. In 
the model, treatment was intensified when A1C exceeded 7.5%, first by adding 
basal insulin and subsequently by adding prandial insulin. Utility decrements and 
U.S. costs associated with key macrovascular and microvascular heath states and 
AEs were sourced from the literature. All costs and benefits were discounted at 
3%. Results: CANA dominated DAPA; CANA was associated with both cost sav-
ings ($3,204) and more Quality Adjusted Life Years (0.22). The reductions in the 
relative risks of microvascular (up to 4.4%) and macrovascular events (up to 1.7%) 
as well as a delay in the use of insulin are the key drivers. cOnclusiOns: This 
simulation suggests that CANA will not only produce cost-savings, but also result 
in QALY gains versus DAPA in the treatment of patients inadequately controlled 
on MET in the US.
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Objectives: To compare the cost-effectiveness of dapagliflozin versus sulfony-
lurea (SU) added to metformin in people with T2DM inadequately controlled on 
metformin alone, in Argentina and Chile. MethOds: A discrete event simulation 
model (Cardiff diabetes model) based on UKPDS 68 was used to simulate disease 
progression and to estimate the economic and health treatment consequences in 
people with T2DM. Epidemiologic and clinical efficacy parameters were obtained 
from the literature. The cost of medication was based on country level drug prices; 
the cost of macro- and microvascular events was based on tariffs from the social 
security system of Argentina and the National Health Insurance (FONASA) of Chile. 
Costs were expressed in US dollars ($). A 20-year time horizon and the payer’s per-
spective were assumed. Costs and health outcomes were discounted at 5% and 
3% in Argentina and Chile, respectively. Deterministic and probabilistic sensitivity 
analyses (PAS) were performed. Results: Comparison of dapagliflozin add-on to 
metformin versus SU addition to metformin showed an incremental benefit of 0.376 
QALYs (95%CI: 0.368; 0.385) in Argentina and 0.422 QALYs (95%CI: 0.411; 0.432) in 
Chile. In both countries, the total cost of the dapagliflozin cohort was higher than 
that of the SU cohort (Incremental cost: Argentina: $3,400; Chile: $2,423). The calcu-
lated Incremental Cost-Effectiveness Ratio (ICER) was $9,036 and $5,745 per QALY 
in Argentina and Chile, respectively. Using WHO’s criteria, dapagliflozin compared 
to the SU treatment strategy has 88% probability for Argentina and 99% for Chile 
of being highly cost-effective (ICER< 1 GDP per capita). The results were robust to 
sensitivity analysis. cOnclusiOns: Dapagliflozin in combination with metformin 
is a cost-effective treatment option for patients who are inadequately controlled 
with metformin monotherapy in Argentina and Chile.
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Objectives: Determine the cost-effectiveness of becaplermin gel* on wound heal-
ing and amputation for the treatment of diabetic foot ulcers (DFUs). MethOds: 
A 4-stage Markov model was used to predict the expected costs and outcomes 
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Objectives: Determine the cost-effectiveness of clostridial collagenase ointment 
(CCO) plus surgical sharp debridement (SSD) relative to the standard of care (SC) plus 
SSD on wound closure for the treatment of diabetic foot ulcer (DFU). SC was defined 
as offloading plus daily wound care/dressings. MethOds: A 3-stage Markov model 
was used to predict the expected costs and outcomes of wound closure for CCO and 
SC. The 3 stages were open wound, epithelialization, and death. Outcome data used 
in the analysis were taken from a randomized clinical trial that directly compared 
CCO and SC. The primary outcome was the proportion of patients achieving a closed 
epithelialized wound. Transition probabilities for the Markov states were estimated 
from the clinical trial. A 52-week time horizon was used to determine the number of 
closed epithelialized wounds and the expected costs for the two therapies. Resource 
utilization was based on the treatment regimen used in the clinical trial. Costs 
were derived from standard cost references and medical supply wholesalers. The 
economic perspective taken was that of the payer. Results: A total of 55 patients 
were included (28 for CCO and 27 for SC). Expected direct costs per patient for DFU 
were $2099 for CCO and $2376 for SC (a cost-savings of $278 for CCO). Patients 
treated with CCO had, on average, 35 ulcer-free weeks compared to 28 weeks for SC. 
CCO therapy had a higher probability of healing at 52 weeks compared to SC (89% 
vs. 80%, respectively). The cost per closed wound week was 1.4 times higher for SC 
compared to CCO ($61/week versus $85/week, respectively). cOnclusiOns: CCO 
was cost-effective over SC, yielding better outcomes at a lower cost in patients with 
DFU. Health care providers should consider CCO as a more effective alternative to 
SC and an effective adjunct therapy to sharp debridement.
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Objectives: To evaluate the cost-effectiveness of canagliflozin in dual therapy (plus 
metformin) compared to sitagliptin and glimepiride, and in triple therapy compared 
to pioglitazone (plus metformin), sitagliptin (plus glimepiride and metformin) and as 
add on to insulin (plus metformin) respectively in the Belgian setting from the public 
payers perspective. MethOds: The IMS CORE Diabetes Model was used to evaluate, 
based on head-to-head clinical trials, the cost-effectiveness of canagliflozin (assum-
ing 70/30 dose distribution for the 100mg and 300mg respectively) versus the afore-
mentioned comparators using Belgian-specific data, where available. Costs were 
obtained from official sources, literature and the IMS Hospital Disease Database and 
are reported in 2013 Euro (€ ).An annual discount rate of 3% was applied on costs 
and 1.5% on effects. Results: The cost-effectiveness analyses indicate that in dual 
therapy when compared with sitagliptin and glimepiride, canagliflozin is expected 
to be cost–effective with an ICER of 6,992 € /QALY gained (with an incremental cost 
and QALY of € 366 and 0.052) and 3,364 € /QALY gained (with an incremental cost 
and QALY of € 410 and 0.122), respectively. In both triple therapies, treatment with 
canagliflozin appears to be a dominant strategy resulting in QALY gains and cost-
savings. As an add on to insulin (plus metformin), canagliflozin is cost–effective with 
an ICER of 11,929 € /QALY gained (with an incremental cost and QALY of € 721 and 
0.060). The deterministic sensitivity analysis revealed that the results are sensitive 
to time horizon (with a time horizon of 10 years the ICER increases to a level in range 
€ 20.000-30.000). Probabilistic sensitivity analysis showed that in all the comparisons, 
canagliflozin appears to be the dominant strategy with a large proportion (about 
48%) of cases being in the south-east quadrant. cOnclusiOns: Canagliflozin 100 
mg or 300 mg (70/30 dose split) provides economic value when used in treatment 
of type 2 diabetes in Belgium.
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Objectives: To evaluate the economic impact of using saxagliptin/metformin XR 
FDC versus sulfonylurea (SU) plus metformin (MET) in Colombia, in people with type 
2 diabetes (T2DM) who do not achieve treatment goal only with MET. MethOds: A 
discrete event simulation model (Cardiff diabetes model) based on UKPDS 68 was 
used to simulate disease progression and to estimate the economic and health 
treatment consequences in people with T2DM. Epidemiologic and clinical efficacy 
parameters were obtained from the literature. Cost of medication was obtained 
from country level drug prices, SISMED and Farmaprecios; cost of macro and micro-
vascular events were based on POS tariffs, SOAT Manual and consultation with a 
local expert. A 20-year time horizon was assumed. Costs and health outcomes were 
discounted at 3% annually. Deterministic and probabilistic sensitivity analysis were 
also performed. Results: The group treated with saxagliptin/metformin XR had 
fewer non-fatal events and episodes of hypoglycemia than the SU plus MET treated 
group. The model also predicted a lower number of fatal macrovascular events for 
the saxagliptin/metformin XR group (159 vs. 162). In both treatment groups the costs 
